Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study authors.elsevier.com/c/1d8Dc5EIIgEB…

Congrats to Dr. Bishoy M. Faltas on another major achievement. eipm.weill.cornell.edu/news/dr-bishoy… Bladder Cancer Advocacy Network UroToday.com Uromigos

“FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors” Big news for #BladderCancer and all advanced cancers FDA Oncology Matt Galsky Andrea Apolo, M.D. Dr. Bishoy M. Faltas Perlmutter Cancer Center at NYU Langone Health

Late breaking research from Bhardwaj Lab, Matt Galsky and colleagues at #AACR2024: Atezolizumab plus neoantigen vaccination for #bladdercancer abstractsonline.com/pp8/#!/20272/p… Poster, April 8, 9-12:30 Icahn School of Medicine at Mount Sinai

In the last 10 years, Tom has led the field and transformed the care of bladder and kidney cancer patients. Very happy to call him a friend and colleague. Congratulations Tom Powles !

Online First: Results from KEYNOTE-057: #Pembrolizumab monotherapy for high-risk non-muscle-invasive #bladdercancer without carcinoma in situ and unresponsive to BCG: a single-arm, multicentre, phase 2 trial #gusm thelancet.com/journals/lanon…

Delighted that Ram stepped up into this important role!

In honor of #BladderCancer Awareness Month, we're highlighting this work by Andrea Apolo, M.D.. Check it out! 👇 National Cancer Institute

Congrats to rising ⭐️ Jon Anker, MD, PhD The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai

It's with great pleasure that I share with you our paper evaluating #cabozantinib with #nivolumab +/- #CBM588 in pts with advanced #kidneycancer, published today in Nature Medicine! 🙏Huge thanks 1st/foremost to patients & their families. Had tons of support from the amazing

We will miss you! Good luck with your new position. I am sure you will be doing great!

Now online European Urology Oncology European Urology Oncology #Enzalutamide Monotherapy in #EMBARK #BCR #ProstateCancer Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity authors.elsevier.com/a/1jLRt9Cfv--d…

Hot off the presses! NCI CCR GU Malignancies NCI Center for Cancer Research great work Ravi A Madan M.D.

Grateful for the 2024 Bladder Cancer Advocacy Network Innovation Award! This exciting collaboration between my lab Weill Cornell Medicine & Jaehee Kim Cornell University will develop Bio-Digital Avatars to personalize treatments by integrating organoids, ctDNA, math models & deep RL bcan.org/2024-bladder-c…

Well deserved

Congratulations Dr. Andre R. Kydd NCI CCR GU Malignancies NCI Center for Cancer Research National Cancer Institute

Dr. Sally Lau presents phase Ib DeLLphi-303: maintenance tarlatamab for #SCLC at #WCLC24. After 4-6 cycles of platinum + etoposide + atezolizumab or durvalumab, given tarlatamab 10mg/kg maintenance + immunotherapy. No new safety signals - low rates of discontinuation from AE.

Dr. Andrea Apolo will be presenting data from the #AMBASSADOR trial of #pembro in #BladderCancer in Sunday’s early session @myesmo #ESMO24 Andrea Apolo, M.D. NCI Center for Cancer Research National Cancer Institute

Congratulations Andrea Apolo, M.D. and team!

NIAGRA presented #ESMO24 and published today NEJM – huge accomplishment 1000+ patients enrolled. Exciting results! Some thoughts on applying them to practice...